Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.

Sherief Abd-Elsalam

Status and phase: Unknown; Phase 3

Conditions: HCC

Treatments: Drug: LMWH; Procedure: TACE

Study type: Interventional

Funder types: Other

Identifiers

NCT02715492

LMWH TACE

Details and patient eligibility

About

Hepatocellular carcinoma (HCC) is a major health problem worldwide, and most cases are inoperable because of late presentation and underlying cirrhosis. It represents the fifth most common tumor in the world and the third most frequent cause of mortality amongst patients with cancer.

Due to the worldwide difficulties in finding liver for transplantation, hepatic resection (HR) represents the main stay of curative treatment for patients with HCC. Transcatheter arterial chemoembolization (TACE) is widely used as alternative treatments for unresectable HCC or for patients not eligible to be operated on .

TACE also could be an adjuvant therapy for resectable HCC patients after hepatectomy, which could prevent recurrence and improve long-term survival .

Full description

Thromboembolism is a well-recognised complication of malignant disease. Clinical manifestations vary from venous thromboembolism to disseminated intravascular coagulation and arterial embolism. Disseminated intravascular coagulation is most commonly observed in patients with haematological malignant disorders and those with wide spread metastatic cancer, whereas arterial embolism is most commonly observed in patients undergoing chemotherapy and in those with non-bacterial thrombotic endocarditis .

The goals of using antithrombotic therapy with TACE in HCC are to minimize mortality and to improve survival rate without provoking excessive bleeding.

Enrollment: 40 estimated patients

Sex: All

Ages: 40 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HCC which was not amenable to surgical resection, liver transplantation or local ablative therapy.
• The lesion had not been previously treated with surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation.
• Reasonable performance status as adequate hematologic function; adequate hepatic function and adequate renal function.
• Child-Pugh class A or B and no portal vein thrombosis.

Exclusion criteria

• Child C patients Portal vein thrombosis

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

Transarterial Chemoembolization

Active Comparator group

Description:

1st group: included 20 patients with HCC treated by TACE only.

Treatment:

Procedure: TACE

TACE and LMWH

Experimental group

Description:

2nd group: included 20 patients with HCC treated by TACE and adjuvant dose of Low Molecular Weight Heparins (LMWH).

Treatment:

Procedure: TACE

Drug: LMWH